Contraline Team

“Great vision without great people is irrelevant.”

Jim Collins

Our Team
View Kevin's bio
Kevin Eisenfrats

Co-Founder and Chief Executive Officer

View Nikki's bio
Nikki Hastings, Ph.D.

Chief Operating Officer

View Greg's bio
Greg Grover, Ph.D.

Vice President of Product

View Nic's bio
Nic Matsumoto, Ph.D.

Principal Scientist

View Rucha's bio
Rucha Bhat

Research Scientist

View Tyler's bio
Tyler Chiartas

Product and Quality Engineer

View Beth's bio
Beth Battista, CRMc

Quality Manager

View Katie's bio
Katie Martin

Office and Lab Coordinator

Interested in joining us?

We are always looking for hard-working, passionate individuals with expertise in various aspects of medical device development and commercialization. If you enjoy working in small teams and solving difficult problems, you'd be a great fit for Contraline.

We are always looking for hard-working, passionate individuals with expertise in various aspects of medical device development and commercialization. If you enjoy working in small teams and solving difficult problems, you'd be a great fit for Contraline.

Board of Directors
Evan Edwards

Evan Edwards is Vice-President of Innovation, Development and Industrialization at kaleo Inc., a pharmaceutical company dedicated to building innovative solutions for serious and life-threatening medical conditions. He is a co-founder of kaléo and co-inventor of the company’s technology platforms. The company’s first approved drug products, Auvi-Q® (epinephrine injection, USP) and Evzio® (naloxone injection, USP) are both emergency use auto-injectors and are commercialized in the U.S. Together these products have saved over 4500 lives. Evan is a graduate of the University of Virginia where he earned a B.S. in Mechanical Engineering and a M.S. in Systems Engineering with a focus on Human Factors Engineering.

Tom Thorpe

Tom Thorpe is CEO of Afton Scientific, a cGMP contract manufacturer of sterile drugs and products for use in new drug development and production. Tom has over 30 years of experience in commercial pharmaceutical operations. He is a member of the Board and the Executive Committee of the Pharmaceutical and Bio-Pharmaceutical Outsourcing Association (BPOA) and previously served as Board Chair of the Virginia Biotechnology Association (Virginia Bio). Tom holds a B.S. in Chemical Engineering from the University of Connecticut and an MBA from University of Virginia.

Kevin Eisenfrats

Kevin Eisenfrats is co-founder and CEO of Contraline. He is an entrepreneur and biomedical engineer who founded Contraline to commercialize the first vas-occlusive male contraceptive. At Contraline, Kevin provides vision, leads business development, commercialization, and intellectual property. He has received numerous awards for the invention behind Contraline and is a Y-Combinator fellow. Kevin received a B.S. in Nanomedicine Engineering from UVA.

Austin Herr

Austin Herr is a Director on Contraline's Board. His background is in Web Development, having receiving a B.S. in Data Modeling and Database Administration, and Masters in Information Technology from Virginia Tech. He also has performed biotech research in Dr. John Herr's lab on the cancer-oocyte antigen SAS1B and is an author on a paper and patent relating to that technology.

Advisory Board
Paul Turek, M.D.

Dr. Paul Turek is an internationally known thought leader in male reproductive medicine. Paul is a fellowship trained, board-certified physician who has received numerous honors and awards for his pioneering work in reproductive urology. Dr. Turek directs The Turek Clinics in San Francisco and Beverly Hills and is an advisor to the NIH, CDC and several biotech startups in Silicon Valley and Los Angeles. Dr. Turek graduated from Yale College, attended medical school at Stanford University, and completed residency training in urology at the University of Pennsylvania. He recently retired as an endowed chair professor of Urology at the University of California San Francisco and now maintains an award winning blog at TurekonMensHealth.com.

Bob Chapin, Ph.D.

Dr. Robert Chapin is an expert in male and female reproductive toxicity. Dr. Chapin served as Senior Research Fellow at Pfizer for 15 years evaluating biomarkers and developing in vitro screening assays for reproductive toxicity. He has first or co-authored 160 scientific papers, book chapters, and reviews. Dr. Chapin was received many awards for his scientific work including from the Society of Toxicology and American Society of Andrology. Dr. Chapin obtained a PhD in Pharmacology from UNC Chapel Hill.

Bill Stilley, MBA

Bill Stilley is a life sciences executive with experience in business development, manufacturing, finance, and M&A. He currently serves as CEO of Adial Pharmaceuticals, a company developing drugs for addiction diseases and disorders. Previously, Bill served as VP of Business Development & Strategic Projects at Clinical Data (NASDAQ: CLDA), as the COO and CFO of Adenosine Therapeutics, and as an advisor to a number of public and private companies. Bill received his B.S. in Commerce from the University of Virginia and MBA from the Darden School of Business.

Dr. John Herr, Co-Founder of Contraline
In memoriam

1948-2016

Contraline is deep rooted in Dr. John Herr's essence. Dr. Herr was a visionary, a scientist, and an entrepreneur at the forefront of reproductive medicine. Contraline is continuing his legacy by developing innovating reproductive health products. Learn more about John here.

1216 Harris Street, Charlottesville, VA 22903
© 2017 Contraline, Inc. All Rights Reserved.